



This table summarizes COVID-19 vaccine eligibility based on the primary series received and the patient age and immune status. The most current version of this table is available [online](#).

Vaccine	Dose	Age				
		5-11	12-17	18-49	50-64	65+
Pfizer ^{1/} Comirnaty & Moderna ²	Primary 2-dose series	Pfizer only ¹	Pfizer only	✓	✓	✓
	Third dose (“additional dose”) ³ recommended for moderate to severely immunocompromised persons <i>at least 28 days</i> after 2 nd dose		Pfizer only	✓	✓	✓
	Booster dose recommended ⁴ <i>at least 6 months</i> after primary series ⁵			✓	✓	✓
Janssen/ Johnson & Johnson (J&J)	Primary single-dose series			✓	✓	✓
	Booster dose recommended ^{4,6} <i>at least 2 months</i> after the 1 st dose			✓	✓	✓
Fully Vaccinated with Alternative Series ⁷	Third dose (“additional dose”) recommended for moderate to severely immunocompromised persons <i>at least 28 days</i> after 2 nd dose		Pfizer only	Pfizer only	Pfizer only	Pfizer only
	Booster dose recommended ⁶ <i>at least 6 months</i> after the 1 st dose			Pfizer only	Pfizer only	Pfizer only

1. Pfizer has a different formulation for the 5-11 age group: 0.2 ml dose containing 10 µg in Tris buffer (orange cap).
2. Moderna has two dose volumes. The full dose (100 µg in 0.5 ml) is authorized for both the primary series and the 3rd dose for persons who are immunocompromised. A half dose (50 µg in 0.25 ml) is authorized for booster doses.
3. The third dose of mRNA vaccine should be the same vaccine product as the primary series, whenever possible.
4. Booster doses can be the same vaccine as was given in the primary series or it can be a mix-and-match dose. Note: a Moderna booster dose is a half dose (50 µg in 0.25 ml).
5. Immunocompromised persons who have had a 3rd dose of mRNA vaccine *may receive* a booster dose \geq 6 months after their 3rd dose. If a Moderna vaccine is used, it should be the booster dose and volume (50 µg in 0.25 ml).
6. All persons who received J&J as their primary dose should get a booster dose (including those who are IC) at least 2 months (8 weeks) later. IC persons who received one primary dose of J&J should not receive more than two COVID-19 vaccines in total-if Moderna is used, it should be the half-dose.
7. Person who are considered [fully vaccinated](#) with a non-FDA authorized/approved series include those who completed a WHO-EUL COVID-19 vaccine series, those who completed a heterologous (mix and match) series composed of any combination of FDA-approved, FDA-authorized, or WHO-EUL COVID-19 vaccines, and those who have received the full series of an “active” (not placebo) COVID-19 vaccine candidate for which vaccine efficacy has been independently confirmed (e.g., by a data and safety monitoring board). Currently this includes participants in the Novavax and AstraZeneca COVID-19 vaccine trials. At this time only the Pfizer COVID-19 vaccine is authorized as a booster or additional dose for people who did not receive an FDA authorized/approved COVID-19 vaccine series.

For more information, see CDC [Clinical Considerations for Use of COVID-19 Vaccines](#).

